Last reviewed · How we verify

uHCG 7500 IU

Eugonia · FDA-approved active Small molecule ✓ Verified May 2026 Quality 0/100

uHCG 7500 IU is a Small molecule drug developed by Eugonia. It is currently FDA-approved. Also known as: Pregnyl 7500 IU.

The uHCG 7500 IU is a small molecule used for ovulation induction in high responders with infertility, as indicated by ClinicalTrials.gov. It is administered as part of a treatment protocol for triggering final oocyte maturation in high responders, as compared to recombinant hCG.

At a glance

Generic nameuHCG 7500 IU
Also known asPregnyl 7500 IU
SponsorEugonia
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about uHCG 7500 IU

What is uHCG 7500 IU?

uHCG 7500 IU is a Small molecule drug developed by Eugonia.

Who makes uHCG 7500 IU?

uHCG 7500 IU is developed and marketed by Eugonia (see full Eugonia pipeline at /company/eugonia).

Is uHCG 7500 IU also known as anything else?

uHCG 7500 IU is also known as Pregnyl 7500 IU.

What development phase is uHCG 7500 IU in?

uHCG 7500 IU is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing